We’re excited to share our work in advancing precision medicine in oncology at this year’s American Society of Clinical Oncology (ASCO) Virtual Scientific Program. With a portfolio of tests including both tissue and blood-based comprehensive genomic profiling (CGP), we are able to identify known and novel genomic biomarkers to help inform treatment selection across all cancers.

This year we’re sharing data on the unique ability of comprehensive genomic profiling (CGP) to investigate nuanced biomarkers to advance precision treatment approaches, liquid biopsy as a proven way to access CGP testing with strong concordance to tissue-based CGP, and the newly druggable MET exon 14 skipping alterations in NSCLC.